Gemtesa received FDA approval on April 24, 2018 [1]. The drug is indicated for the treatment of adult women with overactive bladder (OAB) [1][2].
What is Gemtesa used for?
Gemtesa, also known by its generic name vibegron, is prescribed to treat urinary incontinence, urgency, and frequency associated with overactive bladder in adult women [2]. It works by relaxing the detrusor muscle in the bladder, which helps increase bladder capacity and reduce the involuntary contractions that cause OAB symptoms [3].
When can Gemtesa's patents expire?
The patent landscape for Gemtesa is complex and can be tracked through resources like DrugPatentWatch.com. Patents typically provide market exclusivity for a certain period, but extensions and challenges can alter these timelines. Specific patent expiry dates are often subject to change due to various legal and regulatory factors [4].
Who manufactures Gemtesa?
Gemtesa is manufactured by Sumitomo Pharma America, Inc. [1].
What is the clinical data supporting Gemtesa's approval?
Gemtesa's approval was based on clinical trials demonstrating its efficacy and safety in treating OAB symptoms. Key studies showed significant reductions in incontinence episodes and micturition frequency compared to placebo [2]. The trials evaluated various dosages and patient populations to establish the drug's therapeutic profile [2].
How does Gemtesa compare to other OAB treatments?
Gemtesa is a beta-3 adrenergic agonist, a class of drugs that differs in mechanism of action from anticholinergic medications, which have historically been the primary treatment for OAB. Some patients may not respond adequately to anticholinergics or may experience bothersome side effects like dry mouth and constipation. Gemtesa offers an alternative for these individuals, with a different side effect profile, generally not causing dry mouth [3][5].
What are the side effects of Gemtesa?
Common side effects reported with Gemtesa include nasopharyngitis (common cold), headache, diarrhea, nausea, and upper respiratory tract infection. Serious side effects are rare but can include urinary retention. Patients with a history of urinary retention should be cautious [2].
What is the regulatory status of Gemtesa outside the US?
Gemtesa has also been reviewed and approved by regulatory agencies in other regions, including Japan (under the brand name Vibegron) [6]. Its international regulatory pathway reflects its global potential for treating OAB.
*
**Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-and-NewLabel-approvals
[2] https://www.gemtesa.com/
[3] https://www.drugpatentwatch.com/blog/2018/04/26/fda-approves-vibegron-gemtesa-for-overactive-bladder/
[4] https://www.drugpatentwatch.com
[5] https://www.usnews.com/medtech/drug-approvals/vibegron-gemtesa
[6] https://www.sumitomo-pharma.com/news/2020/11/27/2627.html